-
公开(公告)号：KR101326979B1
公开(公告)日：2013-11-14
申请号：KR1020110009649
申请日：2011-01-31
Applicant: (주)아모레퍼시픽
CPC classification number: C12P17/181
Abstract: 본 발명은 콩을 발아시키는 발아 공정; 및 콩을 발효시키는 발효 공정을 포함하는 쿠메스트롤 생산 방법과 상기 생산 방법에 의해 생산된 쿠메스트롤을 개시한다.
-
公开(公告)号：KR1020130044712A
公开(公告)日：2013-05-03
申请号：KR1020110108914
申请日：2011-10-24
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition containing syringaresinol for treating eye diseases is provided to normalize the function of mitochondria and to prevent or treat eye diseases especially age-related eye diseases. CONSTITUTION: A composition for preventing or treating eye diseases contains 1-80 wt% of syringaresinol. The eye diseases are selected from the group consisting of macular degeneration, uveitis, glaucoma, diabetic retinopathy, and cataract. Syringaresinol is contained in extracts prepared using one or more selected among linseed, Phellodendron amurense Ruprecht, Acanthopanax senticosus, sesame seeds, and ginseng fruits. The composition enhances SIRT 1 expression and mitochondria synthesis. [Reference numerals] (AA) SIRT1 protein expression
Abstract translation: 目的：提供一种含有用于治疗眼睛疾病的丁香ares醇的组合物，用于标准化线粒体的功能，并预防或治疗眼睛疾病，特别是年龄相关的眼睛疾病。 构成：用于预防或治疗眼睛疾病的组合物含有1-80重量％的丁香胺。 眼疾病选自黄斑变性，葡萄膜炎，青光眼，糖尿病性视网膜病变和白内障。 使用一种或多种选自亚麻籽，Phellodendron amurense Ruprecht，Acanthopanax senticosus，芝麻和人参果实中制备的提取物中含有Syringaresinol。 该组合物增强SIRT1表达和线粒体合成。 （AA）SIRT1蛋白表达
-
公开(公告)号：KR1020110060140A
公开(公告)日：2011-06-08
申请号：KR1020090116640
申请日：2009-11-30
Applicant: (주)아모레퍼시픽
IPC: A61K36/481 , A61P21/00 , A61P29/00 , A23L1/30
CPC classification number: A61K36/481 , A23L33/105 , A23V2002/00 , A23V2250/21
Abstract: PURPOSE: A composition containing Astragali Radix extract is provided to promote the expression of PGC1-alpha(peroxisome proliferator-activated receptor gamma coactivator 1-alpha). CONSTITUTION: A composition for promoting body energy consumption and muscle metabolism and strengthen muscle contains 1-80 weight% of Astragali Radix extract as an active ingredient. The composition is a pharmaceutical composition or food composition. The Astragali Radix extract is isolated using leaves, stems, and roots of Astragali Radix. The Astragali Radix extract is prepared by extracting Astragali Radix in 10 time volume of distilled water for three hours, filtering with a Whatman No.1 filter, and freeze-drying at -70°C.
Abstract translation: 目的：提供含有黄芪提取物的组合物，以促进PGC1-α（过氧化物酶体增殖物激活受体γ共激活因子1-α）的表达。 构成：用于促进身体能量消耗和肌肉代谢并增强肌肉的组合物含有1-80重量％的黄芪提取物作为活性成分。 组合物是药物组合物或食物组合物。 黄芪提取物使用黄芪的叶，茎和根进行分离。 黄芪提取物通过在10倍体积的蒸馏水中提取黄芪提取物三小时，用Whatman 1号滤器过滤，并在-70℃下冷冻干燥制备。
-
公开(公告)号：KR1020110028741A
公开(公告)日：2011-03-22
申请号：KR1020090086317
申请日：2009-09-14
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition for improving exercise endurance capacity and recovery capability is provided to form a health food with the composition containing chito-oligosaccharide. CONSTITUTION: A composition for improving exercise endurance capacity and recovery capability contains chito-oligosaccharide as an active component. The chito-oligosaccharide increases the utilization coefficient of internal fat acid of a user and reduces the concentration of lactic acid in blood. The chito-oligosaccharide additionally increases the storage content of glycogen of the user.
Abstract translation: 目的：提供一种用于提高运动耐力和恢复能力的组合物，以形成含有低聚半乳糖的组合物的保健食品。 构成：用于提高运动耐力和恢复能力的组合物含有作为活性成分的低聚半乳糖。 氯低聚糖增加了使用者的内部脂肪酸的利用系数，降低了血液中乳酸的浓度。 氯低聚糖另外增加了使用者糖原的储存量。
-
公开(公告)号：KR101007088B1
公开(公告)日：2011-01-10
申请号：KR1020050135945
申请日：2005-12-30
Applicant: (주)아모레퍼시픽
IPC: A61K36/736 , A61P3/04
Abstract: 본 발명에 의한 지방산 산화 촉진용 조성물은 도인 추출물, 백개자 추출물, 백부근 추출물, 전호 추출물, 천오 추출물, 파두 추출물, 패장근 추출물 및 때죽나무 추출물로 구성된 군 중에서 선택된 하나 이상을 유효성분으로 함유함으로써, 인간 간세포주에서 지방산 산화조절에 중요한 역할을 하는 유전자인 CPT1A(Carnitine Palmitoyl Transferase 1A) 프로모터의 활성을 증가시켜 간에서 CPT1A 유전자 발현을 증가시키고 이를 통해 간에서 지방산의 산화를 촉진시키는 기능을 하며, 더 나아가 비만의 예방 또는 치료, 고지혈증의 예방 또는 치료에 이용될 수 있다.
도인, 백개자, 백부근, 전호, 천오, 파두, 패장근, 때죽나무, 지방산, 산화, CPT1A, 비만, 고지혈증-
Patent Agency Ranking
公开(公告)号：KR1020100134381A
公开(公告)日：2010-12-23
申请号：KR1020090052982
申请日：2009-06-15
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition for promoting the alcoholysis inside a human body is provided to use a post-heating fermented tea extract as an active ingredient for reducing hangover. CONSTITUTION: A composition for promoting the alcoholysis contains a post-heating fermented tea extract using non-pathogenic microorganisms as an active ingredient. The non-pathogenic microorganisms are selected from the group consisting of yeast, lactobacillus, saccharomyces genus, bacillus genus, and aspergillus genus. The composition promotes the activity of alcohol dehydrogenase and acetaldehyde dehydrogenase.
Abstract translation: 目的：提供一种用于促进人体内醇解的组合物，使用后加热发酵茶提取物作为减少宿醉的活性成分。 构成：用于促进醇解的组合物包含使用非致病微生物作为活性成分的后加热发酵茶提取物。 非病原微生物选自酵母，乳杆菌属，酵母属，芽孢杆菌属和曲霉属。 该组合物促进醇脱氢酶和乙醛脱氢酶的活性。
-
57.发明授权ＣＰＴ-１ 유전자의 발현을 특이적으로 전사 단계에서조절하는 화학물질의 스크리닝 방법 및 그 방법으로검색된 제니스테인을 유효 성분으로 포함하는 ＣＰＴ-１발현 촉진제 有权用于表达CPT-1基因的控制剂的筛选方法，以及通过该方法筛选的包含染料木素的CPT-1表达增强子
公开(公告)号：KR100994632B1
公开(公告)日：2010-11-15
申请号：KR1020030095226
申请日：2003-12-23
Applicant: (주)아모레퍼시픽
IPC: C12N15/85
Abstract: 본 발명은, CPT-1 프로모터와 루시퍼라제를 포함하는 재조합 플라스미드; 상기 플라스미드로 형질전환된 Huh7 세포주 (수탁번호: KCLRF-BP-00090); 상기 세포를 이용하는 것을 특징으로 하는, CPT-1 유전자의 발현을 특이적으로 전사 단계에서 조절하는 화학물질의 스크리닝 방법에 관한 것이며,
또한 본 발명은, 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 CPT-1 발현 촉진제; 그리고 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 지방산의 베타 산화 촉진제에 관한 것이다.
제니스테인, CPT-1 유전자, 지방산의 베타 산화촉진제.-
公开(公告)号：KR1020100060634A
公开(公告)日：2010-06-07
申请号：KR1020080119311
申请日：2008-11-28
Applicant: (주)아모레퍼시픽
IPC: A61K31/722 , A61P25/28
CPC classification number: A61K31/722
Abstract: PURPOSE: A composition containing chito-oligosaccharide for mitochondria activation is provided to increase mitochondria DNA level and mitochondria-relating enzyme activation and to prevent and treat neurodegenerative diseases or Parkinson' disease. CONSTITUTION: A composition for mitochondria activation contains chito-oligosaccharide as an active ingredient. The chito-oligosaccharide is chito-oligosaccharide lactate. The composition is used for preventing or treating neurodegenerative disease, brain disease, neural disease, heart disease, liver disease, or muscle disease. The composition also used in preventing or treating Parkinson's disease. The composition is a health food composition or pharmaceutical composition. The active ingredient is contained in 10-90 weight% based on total weight.
Abstract translation: 目的：提供含有用于线粒体活化的低聚半乳糖的组合物以增加线粒体DNA水平和线粒体相关酶活化并预防和治疗神经变性疾病或帕金森病。 构成：用于线粒体活化的组合物含有低聚半乳糖作为活性成分。 所述低聚半乳糖是低聚半乳糖。 该组合物用于预防或治疗神经变性疾病，脑疾病，神经疾病，心脏病，肝脏疾病或肌肉疾病。 该组合物还用于预防或治疗帕金森病。 组合物是保健食品组合物或药物组合物。 活性成分的含量为10-90重量％，基于总重量。
-
59.发明公开ＰＲＰ19 및 ＣＬＩＣ 단백질간의 상호작용을 저해하는물질을 검색하는 방법 및 검색된 물질을 포함하는 조성물 有权筛选能够抑制PRP19和CLIC蛋白之间的相互作用的物质和包含筛选物质的组合物的方法
公开(公告)号：KR1020090057780A
公开(公告)日：2009-06-08
申请号：KR1020070124511
申请日：2007-12-03
Applicant: (주)아모레퍼시픽
IPC: A61K38/00 , G01N33/53 , G01N33/533
CPC classification number: A61K36/185 , A61K8/97 , A61K2236/331 , A61K2236/333 , A61K2236/35 , A61Q19/00 , Y10S514/909
Abstract: A method for searching materials inhibiting the interaction between PRP19 and CLIC protein is provided to inhibit the formation of adipose, prevent and treat the disease mediated by the interaction between PRP19 and CLIC protein. A method for searching a material which inhibits the interaction between PRP19 and CLIC protein comprises: a step of reacting PRP19 protein or it U-box domain and CLIC protein; a step of measuring the amount of probe; and a step of selecting candidate material which decreases the amount of probe. A cosmetic composition contains 0.0001-20 weight% Elaeocarpus sylvestrisvar.ellipticus (Thunb.)Hara extract as an active ingredient. A pharmaceutical composition for preventing and treating obesity contains 0.0001-100 weight% of Elaeocarpus sylvestrisvar.ellipticus (Thunb.)Hara extract.
Abstract translation: 提供了一种搜索抑制PRP19和CLIC蛋白相互作用的材料的方法，以抑制脂肪的形成，预防和治疗由PRP19和CLIC蛋白之间的相互作用介导的疾病。 用于搜索抑制PRP19和CLIC蛋白质相互作用的材料的方法包括：使PRP19蛋白或其U盒结构域和CLIC蛋白质反应的步骤; 测量探针量的一个步骤; 以及选择减少探针量的候选材料的步骤。 化妆品组合物含有0.0001-20重量％的El螨（Thunb。）Hara提取物作为活性成分。 用于预防和治疗肥胖症的药物组合物含有0.0001-100％（重量）的El螨（Thonb。）Hara提取物。
-
公开(公告)号：KR1020080067823A
公开(公告)日：2008-07-22
申请号：KR1020070005217
申请日：2007-01-17
Applicant: (주)아모레퍼시픽
Abstract: A transgenic mouse is provided to show obese-inhibiting characteristic by over-express an isocitrate dehydrogenase 3 alpha(IDH3A), there by being used as a model animal for treating and studying obesity. An expression vector pcDNA-IDH3A comprises: a CMV promoter; an IDH3A gene; and a polyadenylated sequence. A method for preparing a transgenic Mus musculus comprises the steps of: (a) preparing the expression vector pcDNA-IDH3A; and (b) micro-injecting the expression vector into a pronucleus of a Mus musculus fertilized egg. Further, the IDH3A gene is cDNA synthesized from mRNA derived form human heart.
Abstract translation: 提供转基因小鼠以通过过表达异柠檬酸脱氢酶3α（IDH3A）来显示肥胖抑制特征，其被用作用于治疗和研究肥胖症的模型动物。 表达载体pcDNA-IDH3A包含：CMV启动子; IDH3A基因; 和多聚腺苷酸化序列。 一种制备转基因小鼠的方法包括以下步骤：（a）制备表达载体pcDNA-IDH3A; 和（b）将表达载体微注射到小家鼠受精卵的原核中。 此外，IDH3A基因是从人心脏衍生的mRNA合成的cDNA。
-
-
-
-
-
-
-
-
-
Search Results
124
records
(took 0.033 seconds)
